9/103 sources · 2 publishersUpdated Nov 6, 20:41 UTC
Braveheart Bio and Hengrui Pharma present 52‑week data on HRS/BHB‑1893 in obstructive hypertrophic cardiomyopathy
Braveheart Bio and its partner Hengrui Pharma reported results from a 52‑week open‑label extension of a Phase 2 study of the cardiac myosin inhibitor HRS/BHB‑1893 in 42 patients with obstructive hypertrophic cardiomyopathy. The extension showed higher exercise capacity, better symptom scores and a large share of patients achieving a low LVOT gradient. The companies will discuss the data at an investor webcast and plan a fixed‑dose Phase 2b trial.
Why it matters
The company said the durability of efficacy and tolerability strengthens confidence to advance the program in China, which could expand the drug’s market opportunity.
Key facts
- 1The extension enrolled all 42 patients from the original Phase 2 core study. stocktitan.net
- 2At week 52, average peak oxygen uptake rose by 2.7 mL·kg⁻¹·min⁻¹ from the extension baseline. stocktitan.net
- 3The Kansas City Cardiomyopathy Questionnaire Clinical Summary Score increased by a mean of 17.3 points over the same period. stocktitan.net
- 4Seventy‑nine percent of patients recorded a Valsalva LVOT gradient below 30 mmHg at week 52. tradingview.com
- 5No severe or serious adverse events occurred during the 52‑week extension; all treatment‑emergent events were mild or moderate. stocktitan.net
- 6Braveheart Bio will host an investor webcast at 3:35 p.m. CT to discuss the data and a planned Phase 2b fixed‑dose study. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.